109 related articles for article (PubMed ID: 19084566)
1. Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health.
de Vries R; Klok RM; Brouwers JR; Postma MJ
Vaccine; 2009 Feb; 27(6):846-52. PubMed ID: 19084566
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States.
Rupnow MF; Chang AH; Shachter RD; Owens DK; Parsonnet J
J Infect Dis; 2009 Oct; 200(8):1311-7. PubMed ID: 19751153
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology.
Rupnow MF; Owens DK; Shachter R; Parsonnet J
Helicobacter; 1999 Dec; 4(4):272-80. PubMed ID: 10597398
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.
Postma MJ; van Hulst M; De Wolf JT; Botteman M; Staginnus U
Transfus Med; 2005 Oct; 15(5):379-87. PubMed ID: 16202052
[TBL] [Abstract][Full Text] [Related]
6. [A study on the epidemiology of Helicobacter pyroli infection among immigrants in Three Gorges area].
Li G; Li Q; Wang H
Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Apr; 22(2):90-2. PubMed ID: 11860850
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
[TBL] [Abstract][Full Text] [Related]
8. Systemic immunization with unadjuvanted whole Helicobacter pylori protects mice against heterologous challenge.
Harbour SN; Every AL; Edwards S; Sutton P
Helicobacter; 2008 Dec; 13(6):494-9. PubMed ID: 19166414
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori vaccine development: optimisation of strategies and importance of challenging strain and animal model.
Hoffelner H; Rieder G; Haas R
Int J Med Microbiol; 2008 Jan; 298(1-2):151-9. PubMed ID: 17714988
[TBL] [Abstract][Full Text] [Related]
10. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
11. On discounting of health gains from human papillomavirus vaccination: effects of different approaches.
Westra TA; Parouty M; Brouwer WB; Beutels PH; Rogoza RM; Rozenbaum MH; Daemen T; Wilschut JC; Boersma C; Postma MJ
Value Health; 2012 May; 15(3):562-7. PubMed ID: 22583467
[TBL] [Abstract][Full Text] [Related]
12. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
Silfverdal SA; Berg S; Hemlin C; Jokinen I
Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
[TBL] [Abstract][Full Text] [Related]
13. A vaccine against Helicobacter pylori: towards understanding the mechanism of protection.
Aebischer T; Walduck A; Schroeder J; Wehrens A; Chijioke O; Schreiber S; Meyer TF
Int J Med Microbiol; 2008 Jan; 298(1-2):161-8. PubMed ID: 17702653
[TBL] [Abstract][Full Text] [Related]
14. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment.
Altes HK; Dijkstra F; Lugnèr A; Cobelens F; Wallinga J
Epidemiology; 2009 Jul; 20(4):562-8. PubMed ID: 19295437
[TBL] [Abstract][Full Text] [Related]
15. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
16. Helicobacter pylori vaccines: is DNA the answer?
Emancipator D; Nedrud JG; Czinn SJ
Helicobacter; 2006 Dec; 11(6):513-6. PubMed ID: 17083371
[No Abstract] [Full Text] [Related]
17. [Immunization with catalase and UreB two-valence vaccine for preventing Helicobacter pylori infection in mice].
Lin HJ; Yang Q; Li J; Liu Y; Wang QY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):436-7. PubMed ID: 18359706
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori.
Skene CD; Doidge C; Sutton P
Vaccine; 2008 Jul; 26(31):3880-4. PubMed ID: 18547687
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies.
de Greeff SC; Lugnér AK; van den Heuvel DM; Mooi FR; de Melker HE
Vaccine; 2009 Mar; 27(13):1932-7. PubMed ID: 19368774
[TBL] [Abstract][Full Text] [Related]
20. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands.
Marschall T; Kretzschmar M; Mangen MJ; Schalm S
Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1214-25. PubMed ID: 18946359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
